Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Towa to Improve Production Efficiencies and Facilities at Yamagata Plant in Response to Rising Generic Demand
September 3, 2015
- AZ, Daiichi Sankyo Team Up for Development, Commercialization of Nasal Flu Vaccine in Japan
September 3, 2015
- GSK Adjusts Shipments of Hepatitis B Treatment Tenozet Due to Disaster-Stricken Plant Following Tianjin Explosion in China
September 2, 2015
- Pfizer Japan Slapped with Biz Improvement Order over ADR Reporting
September 2, 2015
- Sanofi Names Former Keio University Professor Yuji Sato as R&D Head
September 2, 2015
- Eisai to Develop Insomnia Treatment Lemborexant with Purdue Pharma of US
September 2, 2015
- Genzyme Japan Launches Oral Gaucher’s Disease Treatment Cerdelga
September 2, 2015
- Harvoni, Yervoy, Other New Drugs Hit Japan Market
September 1, 2015
- Baxalta Japan Aims for 6-8% Annual Growth by 2020: President Kawamoto
September 1, 2015
- Merck Serono Initiates Voluntary Recall of Ovulation Inducer Serophene Due to Deviation from In-House Specifications
September 1, 2015
- GSK Paid 9.3 Billion Yen to Physicians, Medical Institutions in 2014
August 31, 2015
- Towa Raises Production Target to 14 Billion Tablets: Pres. Yoshida
August 31, 2015
- Hisamitsu Starts PII Study of Analgesic Transdermal Patch for Lower Back Pain in Japan
August 31, 2015
- Seikagaku to Cease Development of Rheumatoid Arthritis Treatment Licensed from Can-Fite
August 31, 2015
- Takeda Inks Deal with Nanotherapeutics to Expand Vaccine Technology Rights
August 28, 2015
- MTPC Chief Hints at No Major Merger, Plans Departure from Go-It-Alone Policy
August 28, 2015
- Jardiance Reduces Cardiovascular Risks: BI, Lilly
August 28, 2015
- Ono Files for Multiple Myeloma Treatment Carfilzomib in Japan
August 27, 2015
- Lixiana Recommended by UK’s NICE as Venous Thromboembolism Treatment Under National Health Service: Daiichi Sankyo
August 27, 2015
- Tresiba Approved for Pediatric Use: Novo Nordisk
August 27, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…